ArticleMicrobiology spectrum2021
Tigecycline Heteroresistance and Resistance Mechanism in Clinical Isolates of Acinetobacter baumannii.
Article in Microbiology spectrum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Global trends and research profile of antibiotic heteroresistance: a bibliometric and visual analysis.Frontiers in microbiology · 2026Pooled it
- Dual population-level processes contribute to polyclonal ceftiofur heteroresistance in swine-derivedVirulence · 2026Article
- Stepwise evolution of tigecycline resistance in Enterococcus hirae through early IS1216E-mediated tet(L) amplification and subsequent rpsJ mutations.Veterinary research · 2026Article
- Combined effect of eravacycline and omadacycline with other antimicrobial agents against Acinetobacter Baumannii.The Journal of antibiotics · 2026Article
- Virulence and Resistance Mechanisms in Multidrug-ResistantPathogens (Basel, Switzerland) · 2026Review
- Biofilm Formation and the Pore ProteinsAntibiotics (Basel, Switzerland) · 2026Article
- Beyond susceptibility results: understanding the clinical and diagnostic burden of bacterial heteroresistance.Molecular biology reports · 2026Review
- Droplet microfluidics with image texture quantification for detection of rare antibiotic-resistant subpopulations from bloodstream infections.NPJ digital medicine · 2026Article
- Heteroresistance to amikacin inMicrobiology spectrum · 2026Article
- Resistance associated genomic variations for moderate level tigecycline resistance evolution in Acinetobacter baumannii.World journal of microbiology & biotechnology · 2026Article
- Evaluation of a simplified agar-based population analysis profiling as a practical alternative for detecting heteroresistance in clinical bacterial isolates.BMC infectious diseases · 2026Article
- Outer membrane vesicles of carbapenem-resistantMicrobiology spectrum · 2026Article
- Comparative genomics reveals avian Acinetobacter baumannii as antimicrobial resistance reservoirs and bovine strains with elevated pathogenicity.Scientific reports · 2025Article
- Mutations in two-component signaling systems drive experimental evolution of tigecycline and colistin resistance inAntimicrobial agents and chemotherapy · 2025Article
- Evaluation of sulbactam/durlobactam activity and synergy against highly drug-resistantJAC-antimicrobial resistance · 2025Article
- Molecular insights into silver nanoparticle resistance in Acinetobacter baumannii and unique adaptations to ionic silver.npj antimicrobials and resistance · 2025Article
- Genomic insights into ST85 and ST158 belonging to recently emerged global clones of multidrug-resistant Acinetobacter baumannii isolates from Egypt: in vitro assessment of repurposed drug-antibiotic combinations.Annals of clinical microbiology and antimicrobials · 2025Article
- Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms.The Journal of antimicrobial chemotherapy · 2025Article
- Detection of the Tigecycline Resistance-Mediating tet(Y) Gene in Acinetobacter baumannii Isolates from Intensive Care Unit Patients in Pakistan.The American journal of tropical medicine and hygiene · 2025Article
- Synergistic combination of next-generation polymyxin MRX-8 and meropenem against carbapenem-resistantAntimicrobial agents and chemotherapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tigecycline is regarded as a last-resort treatment for multidrug-resistant Acinetobacter baumannii. However, tigecycline resistance in A. baumannii has increased worldwide. In this study, we investigated tigecycline heteroresistance in A. baumannii isolates from South Korea. Antibiotic susceptibility testing was performed on 323 nonduplicated A. baumannii isolates. Among 260 and 37 tigecycline-susceptible and -intermediate-resistant A. baumannii isolates, 146 (56.2%) and 22 (59.5%) isolates were identified as heteroresistant to tigecycline through a disk diffusion assay and population analysis profiling. For selected isolates, an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.